Story
Etsy Stock Jumps on Oppenheimer Upgrade, AI Growth Prospects

Summary
Shares of the e-commerce marketplace rose after Oppenheimer upgraded the stock to 'Outperform' with a $90 price target, citing AI-driven improvements and stabilizing sales data.
Etsy (ETSY) shares rose sharply in pre-market trading after analysts at Oppenheimer upgraded the stock, citing a potential growth inflection driven by artificial intelligence and stabilizing sales trends.
Oppenheimer Lifts Rating
Oppenheimer analyst Jason Helfstein raised his rating on Etsy to "Outperform" from a previous "Perform" rating, assigning a $90 price target. According to the analyst note, the firm believes the company is on the verge of a "meaningful inflection" as it enhances its platform's search and discovery capabilities with AI.
The upgrade marks a significant shift from the firm's prior neutral stance on the e-commerce company's stock.
Data Points to Sales Stabilization
Central to Oppenheimer's thesis is its proprietary web traffic analysis, which suggests a notable improvement in customer activity. The data indicates that key sales trends are improving, making the company's financial targets more achievable.
AdKey points from the analysis include:
- Non-app buyer trends for the third quarter are tracking flat year-over-year.
- This represents a significant improvement from the 3% decline recorded in the second quarter.
- Oppenheimer interprets this data to mean that the high end of Etsy's gross merchandise sales (GMS) guidance for the period is now within reach.
Market Context
Etsy's 3.3% pre-market gain was attributed almost entirely to the company-specific news, as the broader market was largely flat. The S&P 500 and Nasdaq showed little movement, and there was no widespread rally in the e-commerce sector, underscoring the direct impact of the analyst upgrade.
Oppenheimer also noted that a recent partnership between Etsy and payments firm Remitly, which expands payout options for international sellers, provides a secondary layer of support for the company's global growth narrative.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.

Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.

Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.

UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.